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Summary Non-small cell lung carcinoma (NSCLC) is the
most common type of lung cancer. At the time of diagnosis,
a large percentage of NSCLC patients have already developed
metastasis, responsible for extremely high mortality rates.
CXCR4 receptor and focal adhesion kinase (FAK) are known
to regulate such invasive cancer behavior. Their expression is
downregulated by p53 and PTEN tumor suppressors which
are commonly co-inactivated in NSCLC patients and contrib-
ute to metastasis. Therefore, targeting CXCR4 or FAK seems
to be a promising strategy in suppressing metastatic spread of
p53/PTEN deficient NSCLCs. In this study, we first examined
the invasive characteristics of NSCLC cells with suppressed
p53 and PTEN activity using wound healing, gelatin degrada-
tion and invasion assays. Further, changes in the expression of
CXCR4 and FAK were evaluated by RT-qPCR and Western
Blot analysis. Finally, we tested the ability of CXCR4 and
FAK inhibitors (WZ811 and PF-573228, respectively) to sup-
press the migratory and invasive potential of p53/PTEN defi-
cient NSCLC cells, in vitro and in vivo using metastatic
models of human NSCLC. Our results showed that cells with
mutually inactive p53 and PTEN have significantly increased
invasive potential associated with hyperactivation of CXCR4
and FAK signaling pathways. Treatments with WZ811 and
PF-573228 inhibitors significantly reduced migratory and in-
vasive capacity in vitro and showed a trend of improved sur-
vival in vivo. Accordingly, we demonstrated that p53/PTEN
deficient NSCLCs have extremely invasive phenotype and
provided a rationale for the use of CXCR4 or FAK inhibitors
for the suppression of NSCLC dissemination.
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Introduction
Lung cancer is the leading cause of cancer-related deaths
worldwide with less than 18% 5-year patient survival rate
[1]. At the time of diagnosis, about 70% of lung cancer pa-
tients are already at the advanced stage with metastases [2].
Even when diagnosed at the earliest stage, most of the patients
already have micro-metastases [3]. Such frequent presence of
lung cancer metastases significantly affects efficiency of con-
ventional therapies and it is a major cause of treatment failure
and high mortality rate associated with lung cancer [4].
Therefore, in the era of developing personalized cancer treat-
ments, special efforts are focused on identifying novel
targeted NSCLC therapies that could also interfere with the
process of metastasis [5].
Cancer cells with higher ability to metastasize are often
characterized by altered expression of different marker pro-
teins involved in adhesion, migration and invasion, such as
CXCR4, FAK, and their related signaling molecules [6].
Chemokine receptor, CXCR4, is highly overexpressed in
NSCLC and plays an important role in its pathogenesis, as
well as in metastasis [7, 8]. CXCR4 exerts its biological ef-
fects, at least partially, by activating downstream phosphory-
lation of FAK, one of the key molecules in regulating cell
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adhesion and motility [9, 10]. Expression of both CXCR4 and
FAK is negatively regulated by p53 and PTEN tumor suppres-
sors [11–14]. Apart from being among the most frequently
mutated genes in NSCLC [15], these two tumor suppressors
have been found to be simultaneously altered in a significant
number of NSCLC patients and associated with metastatic
spread and dramatically shorter survival [16]. Although the
individual contribution of these tumor suppressors in lung
cancer metastasis is well known [17, 18], the effect of their
mutual inactivation has not been elucidated so far. Here we
propose that p53 and PTEN might cooperatively regulate
CXCR4 and FAK expression that seems to promote an ex-
tremely metastatic phenotype and that targeting CXCR4 or
FAK may be a promising strategy in suppressing the metasta-
tic spread of p53/PTEN deficient NSCLCs.
Therefore, we first examined the invasive capacities of
NCI-H460 cells where the activity of p53 and PTEN was
simultaneously pharmacologically inhibited and COR-L23
cells that have intrinsically inactive both tumor suppressors
(http://cancer.sanger.ac.uk/cell_lines). We further evaluated
the expression of CXCR4 and FAK and their downstream
signaling molecules as common targets of p53 and PTEN
activity and finally, tested the ability of CXCR4 and FAK
inhibitors to suppress the migratory and invasive capacities
of NSCLC cells, in vitro and in vivo. Our data showed that
joint inactivation of p53 and PTEN in NSCLC cells resulted in
an extremely invasive phenotype. The obtained results
suggest, under the experimental conditions tested herein, that
CXCR4 and FAK inhibitors could be a valuable targeted
therapy towards inhibiting migration and invasion of p53/
PTEN deficient NSCLCs.
Materials and methods
Cells and cell cultures
NCI-H460 and COR-L23 cell lines were purchased from the
American Type Culture Collection (ATCC, Rockville, MD)
and European Collection of Cell Cultures (ECACC, Salisbury,
UK), respectively. All the cells were maintained in RPMI
1640, supplemented with 10% FBS, 2 mM L-glutamine,
4.5 g/l glucose, 10,000 U/ml penicillin, 10 mg/ml streptomy-
cin, 25 μg/ml amphotericin B solution at 37 °C in a humidi-
fied 5% CO2 atmosphere.
Drugs and treatments
CXCR4 antagonist WZ811, FAK inhibitor PF-573228 and
p53 inhibitor Pifitrin-α (PFT-α) were obtained from
Selleckchem (Houston, Texas, USA). PTEN inhibitor,
bpV(HOp i c ) , wa s pu r cha s ed f rom San t a Cruz
Biotechnology (Dallas, USA). All inhibitors were disolved
in DMSO (Sigma-Aldrich Chemie Gmbh, Germany) to
10 mM stocks and stored at −20 °C. Before treatment, all
drugs were freshly diluted in sterile water.
To achieve individual or simultaneous inactivation of p53
and PTEN tumor suppressors, NCI-H60 cells were treated
with 10 μM PFT-α and 2.5 μM bpV(HOpic), alone and in
combination, for 24 h. Drugs were administered 24 h after cell
seeding. Cells treated with PFT-α and bpV(HOpic), alone and
in combination, from here on are designated as NCI-H460p53-,
NCI-H460PTEN- and NCI-H460p53-/PTEN- cells, respectively.
To evaluate the effects of FAK and CXCR4 inhibitors,
NCI-H460p53-/PTEN- and COR-L23 cells were treated with
1 μM PF-573228 and 1 μM WZ811 for 24 h. In NCI-
H460p53-/PTEN- cells these treatments were administrated 2 h
after the co-treatments with p53 and PTEN inhibitors.
RNA extraction and reverse transcription reaction
Total RNA was isolated using Trizol® reagent (Invitrogen
Life Technologies, USA) according to the manufacturer’s in-
structions. RNA was quantified by spectrophotometry and
quality was determined by agarose gel electrophoresis.
Reverse transcription reactions were performed using 2 μg
of total RNA, with a High-capacity cDNA reverse transcrip-
tion kit (Applied Biosystems, USA), following the manufac-
turers’ instructions.
Quantitative real-time PCR
Quantitative real time PCR (qPCR) was used to analyze the
differences in CXCR4, FAK and PTEN gene expression level.
Reactions were performed by Maxima SYBR Green/ROX
qPCR Master Mix (Thermo Scientific, USA) on an ABI
PRISM 7000 Sequence Detection System (Applied
Biosystems, USA) according to the manufacturer’s recom-
mendations, using 100 ng cDNAs and primers specific for
each gene and ACTB as internal control for normalization
[19–22]. Each sample was tested in triplicate and relative gene
expression was analyzed by 2−ΔΔCt method [23].
Flow cytometric analysis
CXCR4 protein level was detected by flow cytometric analy-
sis. Adherent cells were harvested by trypsinization, washed
in PBS and fixed in 4% paraformaldehyde for 10 min at room
temperature. Cells were then permeabilized by adding ice-
cold 100% methanol for 30 min at 4 °C. After washing in
PBS, cells were blocked for 1 h with 0.5% BSA in PBS.
Cells were then resuspended in primary antibody (mouse
anti-CXCR4; Invitrogen, 35-8800) diluted in 0.5% BSA
(1:100) and incubated overnight at 4 °C. After washing in
PBS, cells labeled with unconjugated primary antibody were
resuspended in secondary antibody (Alexa Fluor 488 goat
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anti-Mouse IgG(H+L); Invitrogen, A-11001) diluted in 0.5%
BSA (1:1000) and incubated for 1 h at room temperature.
Cells were subsequently washed and resuspended in 1 ml of
PBS. The fluorescence intensity was measured in FL1-H
channel on CyFlow Space flow cytometer and analyzed by
Summit analysis software.
Western blot analysis
Western blot analysis was used to analyze the differences in
pFAK, pAKTand pERK level Proteins were isolated in RIPA
buffer containing complete protease and phosphatase inhibitor
cocktails (Roche, Mannheim, Germany). Subsequently, 30 μg
of protein per lane were separated by 10% SDS-PAGE and
transferred onto PVDF membranes. The membranes were
blocked in 1% bovine serum albumin in Tris- buffered sa-
line/0.1% Tween-20 (TBST) for 1 h at room temperature
and incubated overnight at 4 °C with the following primary
rabbit antibodies: anti-AKT (1:1000; Santa Cruz, sc-8312),
anti-pAKT (1:750; Abcam, 81283), anti-ERK (1:1000;
Santa Cruz, sc-94), anti-pERK (1:1000; Santa Cruz, sc-
16982), anti-FAK (1:1000; Invitrogen, 701094) and anti-
pFAK (pY397) (1:1000; Invitrogen, 44-625G). After several
rinses in TBST, the membranes were incubated for 1 h/RT
with a Horse Radish Peroxidase (HRP)-conjugated bovine
anti-rabbit secondary antibody (1:5000; Abcam, 97051).
Immuno r e a c t i v i t y wa s d e t e c t e d by enh an c e d
chemiluminiscence (ECL, GE Healthcare) and exposed to
film (Kodak Biomax). Each blot was re-probed with a primary
mouse β-actin (1:5000; Santa Cruz, sc-8432) and GAPDH
(1/5000; Biolegend, 649202) antibody and incubated with
an anti-mouse secondary antibody (1:10,000; Cell Signaling,
7076S). All antibodies were diluted in TBST. Signals were
quantified by densitometry using Image Quant software (v.
5.2, GE Healthcare) and expressed as relative values (i.e.,
density ratio normalized to the corresponding internal control,
β-actin or GAPDH signal).
Wound healing assay
In order to evaluate the migratory potential cells were seeded
in 24-well plates and grown for 24 h. Upon reaching conflu-
ence, a uniform wound was scratched into a monolayer of
each well with a sterile plastic 200 μl micropipette tip. After
wounding, tissue culture medium was replaced and described
treatments were applied. Wound closure was monitored by
imaging cells at 2× magnification on a Leica microscope
(Leica Microsystems GmbH, Wetzlar, Germany) immediately
and 24 h after wounding. The captured images were analyzed
by ImageJ software (NIH, USA) to measure the degree of
closure of the wounded area. Independent experiments were
performed at least three times.
Gelatin degradation assay
To compare the ability of cells to degrade gelatin cells were
seeded in 6-well plates with glass coverslips coated with
AlexaFluor488 labeled gelatin (Gelatin From Pig Skin,
Oregon Green® 488 Conjugate, Life Technologies, USA) at
a density of 50,000 cells/well. After 24 h treatments, the cells
were fixed with 4% paraformaldehyde and stained with
Hoechst 33342 (Sigma-Aldrich Chemie Gmbh, Germany)
and ActinRed 555 (Life Technologies, USA) for 1 h at room
temperature. Cells and matching degraded gelatin areas were
analyzed at 20×magnification under a Zeiss Axiovert inverted
fluorescent microscope (Carl Zeiss Foundation, Germany)
equipped with AxioVision 4.8 Software. The volume of the
dark areas caused by gelatin degradation was measured using
ImageJ software and normalized to the volume of the cell. At
least 100 cells were analyzed per experiment. All experiments
were performed at least three times.
Invasion assay
Next, to study the invasive capacity we used Transwell
inserts (membrane pore size, 8 μm; diameter, 6.4 mm;
BD Biosciences Discovery Labware) placed in 24-well
plates. 200,000 cells were seeded in serum free medium
in the upper chambers covered with a layer of Matrigel
Basement Membrane Matrix (BD Biosciences) (500 g/
ml). The lower chambers were filled with RPMI-1640
medium supplemented with 10% FBS as chemoattractant.
A control sample without 10% FBS, as a measurement of
spontaneous cell invasion, was included in each experi-
ment. After the incubation, cells that invaded through the
Matrigel and its underlying membrane were fixed in 4%
paraformaldehyde-PBS and stained with Hoechst 33342.
The cells that failed to invade remained on the upper
surface and were carefully removed with a cotton swab,
whereas the cells on the lower surface of the membranes
were counted under a Zeiss Axiovert inverted fluorescent
microscope at a 10× magnification. The average number
of cells in 30 independent fields per membrane was ana-
lyzed. At least 3 independent experiments were per-
formed. The results are presented as percentage of cells
that invaded through the matrigel-coated membrane com-
pared to the untreated control.
In vivo tumorigenicity assays
Eight weeks old NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)
mice and 8–10 week-old SCID (Severe Combined
Immunodeficiency) mice were used for in vivo experiments.
All animal procedures were in compliance with Directive
(2010/63/EU) on the protection of animals used for experi-
mental and other scientific purposes and were approved by
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the IACUC and the local Directorate-General for Regional
Rural Economy and Veterinary (Lisence No 5542/228006).
All mice were housed under pathogen-free conditions in the
animal facility in a controlled environment (12 h dark/light
cycles), fed with standard laboratory chow, and given
autoclaved water.
For the in vivo tumorigenicity assays, subcutaneous
injections were performed in each axillary region of the
rear flanks. On the day of inoculation, NCI-H460 and
COR-L23 cells were counted and diluted in 100 μl
RPMI medium. Two different inoculation densities
(100,000 and 10,000 cells) for both cell lines were used
in NSG mice to evaluate their tumorigenic potential.
Formation of palpable tumors was monitored over time.
To investigate the growth rate of NCI-H460 and COR-
L23 cells derived xenografts 106 cells of each cell line
were injected in SCID mice. Mice were monitored three
times a week for tumor growth. Tumor size was measured
with a caliper and tumor volume was calculated using the
formula V (mm3) = a × b2/2, where V (mm3) is the tumor
volume in mm3, a = length and b = width of the tumors.
Each group in both types of in vivo experiments consisted
of 3 mice, with 2 inocula per mice. The experiments were
terminated when the tumor size reached a volume of
1500 mm3 (about 11% of the mouse weight).
Orthotopic metastatic xenograft model
The model was established following the procedure described
by Kraus-Berthier et al. [24]. Briefly, animals were anesthe-
tized with Ketamin (Imalgene 1000, Merial) at 10 mg/kg and
Xylazin (Sedaxylan, EuroVet) at 2 mg/kg, administered i.p.
On the day of inoculation, NCI-H460 and COR-L23 cells
were counted and diluted in 100 μl RPMI medium. NCI-
H460 and COR-L23 cells were implanted at 1 × 106 and
5 × 105 inoculation densities through the chest wall into the
left pleural space of SCID mice (i.pl.) in a volume of 100 μl
using a 26 gauge needle. Each group consisted of 5 mice. One
mouse from each group was sacrificed on day 14 to evaluate
metastatic spread of NCI-H460 and COR-L23 derived
tumors.
In vivo antitumor activity
Vehicle control and both inhibitors, PF-573228 and WZ811,
diluted in WFI (water for injection) with 10% DMSO and 5%
Tween 80, were administered i.p. 5 days in a row to NCI-
H460- and COR-L23-bearing mice, starting 7 days after cell
inoculation. Each treated group consisted of 4 mice, and con-
trol groups consisted of 7 mice. Animal mortality was checked
daily, and the antitumor activity was evaluated comparing
survival times.
Statistical analysis
Statistical analyses were performed byGraphPad Prism 6. The
data obtained by qRT-PCR, wound healing, invasion tests,
Western blotting and in vivo experiments were analyzed by
Student t-test. Gelatin degradation data did not have a normal
distribution, so the Wilcoxon matched-pairs signed rank test
was carried out. Survival analyses were performed using
Kaplan and Meier product-limit method. The log rank test
was used to assess the significance of the difference between
pairs of survival probabilities. The observed differences were
considered statistically significant if p < 0.05.
Results
p53 and PTEN inhibition and functional status assessment
in NSCLC cell lines
To test whether activities of p53 and PTEN tumor suppressors
simultaneously influenced cell invasion, we pharmacological-
ly inactivated p53 and PTEN in NCI-H460 cell line that is a
wild type for both tumor suppressors (http://cancer.sanger.ac.
uk/cell_lines). We used the well-known inhibitor of p53
(Pifitrin-α, PFT-α) in a 10 μM concentration previously
shown to be efficient in NCI-H460 cells [25]. The efficacy
of PTEN inhibitor (bpV(HOpic)) was determined by analyz-
ing the level of pAKT in NCI-H460 cells treated with 1 μM
and 2.5 μM bpV(HOpic). Western blot analyses have shown
that 2.5 μM bpV(HOpic) successfully inhibited activity of
PTEN by increasing AKT phosphorylation 1.7 fold compared
to untreated NCI-H460 cells (Fig. 1a; p = 0.02). Combined
treatment with 10μMPFT-α and 2.5 μMbpV(HOpic) did not
have anti-proliferative effect on NCI-H460 cells, as shown in
Online Resource 1a.
Additionally, we used COR-L23 cell line with intrinsically
mutated and inactivated p53 (http://cancer.sanger.ac.uk/cell_
lines). By comparing PTEN gene expression level between
COR-L23 and NCI-H460 cells using qRT-PCR, we demon-
strated that COR-L23 cells have innately suppressed PTEN
function. Namely, COR-L23 cells showed 11.5-fold decreased
expression of PTEN compared to NCI-H460 cells (Fig. 1b;
p = 0.0002). Such difference in PTEN expression between
these two cell lines affected the level of pAKT protein as
assessed by Western blot analysis. The level of pAKT in
COR-L23 cells was increased 6.8 fold compared to NCI-
H460 cells (Fig. 1c; p = 0.0003).
Increased invasive potential of NSCLC cell lines
with mutually inactivated p53 and PTEN
To examine whether the simultaneous inhibition of p53
and PTEN influenced invasive capacity of NCI-H460
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cells, we analyzed migration and invasion of these cells
treated with 10 μM PFT-α and 2.5 μM bpV(HOpic),
alone (NCI-H460p53- and NCI-H460PTEN- cells, respec-
tively) and in combination (NCI-H460p53-/PTEN- cells)
using wound healing, invasion and gelatin degradation
assays. Specifically, only combined treatment with
PFT-α and bpV(HOpic) significantly increased cell mi-
gration in the wound healing assay 1.4-fold (Fig. 2a;
p = 0.0052) compared to untreated cells. In invasion and
gelatin degradation assays, we observed greater capacity
of NCI-H460 cells to invade matrigel (Fig. 2b; 1.7-fold;
p = 0.0043) and degrade gelatin (Fig. 2c; 1.9-fold;
p = 0.0003) after functional inhibition of p53 and PTEN.
Moreover, COR-L23 cells with mutated p53 and signifi-
cantly lower expression of PTEN showed a similar pattern of
migration and invasion to NCI-H460 cells with these two
Fig. 1 PTEN inhibition and
functional status assessment in
NSCLC cell lines. a
Quantification of pAKT level by
Western blotting in NCI-H460
cells treated with 1 μM and
2.5 μM bpV(HOpic). b
Quantitative real-time PCR
analyses of PTEN gene
expression in COR-L23 cells
compared to NCI-H460 cells. The
expression of target gene was
normalized to the ACTB gene as
internal control and is presented
as a relative value compared to
NCI-H460 cells. All results
represent mean values ± S.E. *
indicates significantly different
level compared to untreated NCI-
H460 cells. c Quantification of
pAKT level by Western blotting
in COR-L23 cells compared to
NCI-H460 cells. The data from
Western blotting experiments are
expressed as the level of phospho-
protein relative to total protein
level, all normalized to β-actin,
from at least three independent
experiments and are presented as
mean value ± S.E. Each graph is
accompanied by representative
Western blots. * indicates p < 0.05
compared to control NCI-H460
cells
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tumor suppressors simultaneously inhibited (Fig. 2). More
precisely, COR-L23 cells migrated at 4 times higher rate than
untreated NCI-H460 cells (Fig. 2a; p = 0.0005), exhibited a 2-
fold increase in invasion through matrigel (Fig. 2b;
p = 0.0022) and had a 2.4-fold increase in degradation of
gelatin (Fig. 2c; p = 0.0001).
Importantly, NCI-H460p53-/PTEN- and COR-L23 cells, both
with dual p53 and PTEN inactivation, had also significantly
increased invasion and gelatin degradation compared to NCI-
H460 cells with individually inhibited p53 and PTEN, as
pointed out in Fig. 2b and c. This was also true for the migra-
tory capacity of COR-L23 cells (Fig. 2a).
Fig. 2 Invasive potential of NSCLC cell lines with inactivated p53 and
PTEN. a Wound healing assay of NCI-H460, NCI-H460p53-, NCI-
H460PTEN-, NCI-H460p53-/PTEN- and COR-L23 cells. Histograms for
each cell type showing relative wound closure compared to NCI-H460
cells are presented along with representative images, taken immediately
(T 0) and 24 h (T 24) after wounding. b Invasion of NCI-H460, NCI-
H460p53-, NCI-H460PTEN-, NCI-H460p53-/PTEN- and COR-L23 cells.
Histograms for each cell type are presented along with representative
images showing Hoescht 33342 stained nuclei of cells that invaded
through the Matrigel to the opposite side of the membrane. Scale
bar = 500 μm. c Gelatin degradation by NCI-H460, NCI-H460p53-,
NCI-H460PTEN-, NCI-H460p53-/PTEN- and COR-L23 cells. Histograms
showing percentages of degraded gelatin areas relative to the cell
volume for each cell line are presented together with representative
images. Merged channels show fluorescent gelatin (green), actin (red)
and nuclei (blue) staining; dark areas represent spots of degraded
gelatin. Scale bar = 100 μm. For all histograms each bar represents
mean value ± S.E. * indicates p < 0.05 compared to NCI-H460 cells, #
indicates p < 0.05 compared to NCI-H460p53-, $ indicates p < 0.05
compared to NCI-H460p53-/PTEN- cells
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Increased expression of CXCR4, FAK, AKT and ERK
in NSCLC cell lines with mutually inactivated p53
and PTEN
Next, we investigated the expression level of CXCR4 and
FAK, and other downstream signaling molecules, such as
AKT and ERK, upon functional inhibition of p53 and
PTEN. We analyzed their expression by qRT-PCR and
Western blot analyses in NCI-H460 cells treated with 10 μM
PFT-α and 2.5 μMbpV(HOpic), alone and in combination, as
well as in COR-L23 cells. Specifically, CXCR4 protein level
was quantified by flow cytometry. We found that NCI-
H460p53- and NCI-H460p53-/PTEN- cells had significantly in-
creased expression of CXCR4 mRNA 1.8-fold (Fig. 3a;
p = 0.047) and 2-fold (Fig. 3a; p = 0.022), compared to un-
treated cells, respectively. In contrast, the FAKmRNA expres-
sion level remained unchanged upon all treatments in NCI-
H460 cell line (Fig. 3b). COR-L23 cells had significantly
increased expression of CXCR4 and FAK mRNAs compared
to NCI-H460 cells 3.1-fold (Fig. 3a; p = 0.008) and 1.7-fold
(Fig. 3b; p = 0.01), respectively. On protein level, simulta-
neous functional inhibition of p53 and PTEN in NCI-H460
cells significantly increased CXCR4 level 2.7 fold (Fig. 4a;
p = 0.0046) and induced FAK activation 1.7-fold (Fig. 4b;
p = 0.007). In addition, we found that functional inhibition
of p53 and PTEN in NCI-H460 cells, alone and in combina-
tion, led to significant changes in the level of pAKTcompared
to untreated NCI-H460 cells (Fig. 4c). More precisely, NCI-
H460p53- and NCI-H460PTEN- cells showed significant in-
crease in AKT phosphorylation 1.7 fold (p = 0.003) and 1.7-
fold (p = 0.004) compared to NCI-H460 cells, respectively.
Most importantly, NCI-H460p53-/PTEN- cells had the most pro-
nounced effect on the AKT phosphorylation with 3-fold
increase compared to NCI-H460 cells (Fig. 4c; p = 0.001).
pERK level was changed only in NCI-H460p53-/PTEN- cells
exhibiting 2.7-fold increase compared to untreated NCI-
H460 cells (Fig. 4d; p = 0.042).
Level of CXCR4 and activation of FAK, AKT and ERK
was significantly increased in COR-L23 compared to NCI-
H460 cells 5.2 fold (Fig. 4a; p = 0.001), 2.1-fold (Fig. 4b;
p = 0.015), 6.8-fold (Fig. 4c; p = 0.002) and 3-fold (Fig. 4d;
p = 0.037), respectively.
FAK and CXCR4 inhibitors suppressed invasiveness
of NSCLC cell lines with inactivated p53 and PTEN tumor
suppressors
To evaluate whether NSCLC cells with mutual inactivation of
p53 and PTEN (NCI-H460 p53-/PTEN- and COR-L23) could be
responsive to FAK and CXCR4 inhibition, cells were treated
with PF-573228 (FAK inhibitor) and WZ811 (CXCR4 inhib-
itor) and the changes in their invasive properties were ana-
lyzed. Both inhibitors, used in 1 μM concentrations, did not
have considerable anti-proliferative effects on NCI-H460 p53-/
PTEN- and COR-L23 cells (Online Resource 1b and c). In
wound healing assay, we observed that NCI-H460 p53-/PTEN-
cells treated with 1 μMPF-573228 and 1 μMWZ811, migrat-
ed at 1.34-fold (p = 0.001) and 1.42-fold (p = 0.001) slower
rate, respectively, compared to untreated NCI-H460 p53-/PTEN-
cells (Fig. 5a). More pronounced effects of the treatments
were observed in invasion and gelatin degradation assays.
NCI-H460 p53-/PTEN-cells treated with PF-573228 and
WZ811 had a significantly decreased invasion capacity, 4.7
(Fig. 5b; p = 0.0002) and 6.2 (Fig. 5b; p = 0.0001) fold,
respectively. In addition, NCI-H460 p53-/PTEN- cells treated
with PF-573228 and WZ811 degraded gelatin significantly
Fig. 3 Quantitative real-time PCR analyses of a CXCR4 and b FAK
genes expression in NCI-H460, NCI-H460p53-, NCI-H460PTEN-, NCI-
H460p53-/PTEN- and COR-L23 cells. The expression of target genes was
normalized to the ACTB as internal control and is presented as a relative
value compared to NCI-H460 cells. All results are presented as mean
value ± S.E. * indicates p < 0.05 compared to NCI-H460 cells, #
indicates p < 0.05 compared to NCI-H460p53-, $ indicates p < 0.05
compared to NCI-H460p53-/PTEN- cells
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less compared to untreated cells, 5.8 (Fig. 5c; p = 0.0001) and
5.1 (Fig. 5c; p = 0.0001) fold, respectively.
The invasive behavior of COR-L23 cells upon PF-573228
and WZ811 treatments was similar to that observed in NCI-
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H460 p53-/PTEN- cells treated with FAK and CXCR4 inhibitors.
According to wound healing assay, COR-L23 cells treated with
1 μM PF-573228 migrated at 1.6 times slower rate than un-
treated cells (Fig. 5d; p = 0.037), while COR-L23 cells treated
with 1 μM PF-573228 and 1 μM WZ811 exhibited 2.8-fold
(Fig. 5e; p = 0.0001) and 2.6-fold (Fig. 5e; p = 0.0001) decrease
in invasion, respectively. In addition, COR-L23 cells treated
with 1 μM PF-573228 and 1 μM WZ811 degraded gelatin
2.2-fold (Fig. 5f; p = 0.0001) and 2.5-fold (Fig. 5f;
p = 0.0001) more than untreated cells, respectively.
Downregulation of pFAK and pAKT level in NSCLC cell
lines treated with FAK and CXCR4 inhibitors
To examine molecular changes after the treatments with
PF-573228 and WZ811 we analyzed level of pFAK,
pAKT and pERK in untreated and treated NCI-H460
p53-/PTEN-and COR-L23 cells. NCI-H460 p53-/PTEN- cells
treated with PF-573228 and WZ811 exhibited significant
reduction in FAK phosphorylation, 2.6-fold (Fig. 6a;
p = 0.0001) and 2.1-fold (Fig. 6a; p = 0.0001), respec-
tively. In addition, both PF-573228 and WZ811 treat-
ments, led to a 2.6-fold decrease of pAKT in NCI-H460
Fig. 4 Expression analyses of CXCR4, FAK, AKTand ERK in NSCLC
cell lines with inactivated p53 and PTEN. Quantification of (a) CXCR4
level by flow cytometry and (b) pFAK, (c) pAKT and (d) pERK level by
Western blotting in NCI-H460, NCI-H460p53-, NCI-H460PTEN-, NCI-
H460p53-/PTEN- and COR-L23 cells. The quantification and statistical
analysis of flow-cytometric measurements are presented on the left part
of the panel (a). A minimum of 10,000 events were collected for each
sample. At least three independent experiments were performed. Plots of
the representative experiments for each cell line are presented on the right
side of the panel. TheWestern blot data are expressed as level of phospho-
protein relative to the total protein level, all normalized to β-actin or
GAPDH. Each graph is accompanied by representative Western blots.
All results are presented as mean value ± S.E. * indicates p < 0.05 com-
pared to NCI-H460 cells, # indicates p < 0.05 compared to NCI-H460p53-,
$ indicates p < 0.05 compared to NCI-H460p53-/PTEN- cells
Fig. 5 Effects of FAK and CXCR4 inhibitors on invasive characteristics
of NSCLC cell lines with inactivated p53 and PTEN. Wound healing
assay of NCI-H460p53-/PTEN- (a) and COR-L23 (d) cells treated with
1 μM PF573228 and 1 μM WZ811. Histograms for each cell type
showing relative wound closure compared to NCI-H460 cells are
presented along with representative images, taken immediately (T 0)
and 24 h (T 24) after wounding. Invasion of NCI-H460p53-/PTEN- (b)
and COR-L23 (e) cells treated with 1 μM PF573228 and 1 μM
WZ811. Histograms for each cell type are presented along with
representative images showing Hoescht 33342 stained nuclei of cells
that invaded through the Matrigel to the opposite side of the membrane.
Scale bar = 500 μm. Gelatin degradation by NCI-H460p53-/PTEN- (c) and
COR-L23 (f) cells treated with 1 μM PF-573228 and 1 μM WZ811.
Histograms showing percentages of degraded gelatin areas relative to
the cell volume for each cell line are presented together with
representative images. Merged channels show fluorescent gelatin
(green), actin (red) and nuclei (blue) staining; dark areas represent spots
of degraded gelatin. Scale bar = 100 μm. For all histograms each bar
represents mean value ± S.E. * indicates p < 0.05 compared to
corresponding untreated cells, NCI-H460p53-/PTEN- or COR-L23 cells
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p53-/PTEN- cells (Fig. 6b; p = 0.0015 and p = 0.0008,
respectively). However, neither treatment caused pERK
changes in NCI-H460 p53-/PTEN- cells (Fig. 6c).
COR-L23 cells treated with PF-573228 exhibited signifi-
cant reduction in the phosphorylation of FAK andAKT, 2-fold
(p = 0.0018) and 1.5-fold (p = 0.015), respectively, while
WZ811 did not change the level of these proteins (Fig. 6d
and e). The level of pERK remained unchanged upon both
treatments in COR-L23 cells (Fig. 6f).
In vivo tumorigenicity, metastatic spread
and anti-invasive treatment of COR-L23 derived tumors
As we have shown that cells with inactivated p53 and PTEN
exhibited more aggressive phenotype responsive to anti-
invasive treatments with CXCR4 and FAK inhibitors, we fur-
ther aimed to verify these findings in vivo. We first developed
subcutaneous lung cancer human-to-mouse xenografts to
compare the tumorigenicity of NCI-H460 and COR-L23 cells.
Then, we investigated the invasive and metastatic potential of
both cell lines in orthotropic metastatic lung carcinoma mouse
models which we further used to test anti-invasive effects of
CXCR4 and FAK inhibitors.
Tumorigenicity was followed after subcutaneous inocula-
tion of 10,000 and 100,000 of either NCI-H460 or COR-L23
cells in NOD scid gamma (NSG) mice. In these models we
observed that COR-L23 tumors were developed faster in both
inoculation densities as compared to NCI-H460 tumors
(Table 1). More specifically, first palpable tumor was noticed
in COR-L23 xenografts at day 15 following 10,000 cells’
Fig. 6 Effects of FAK and CXCR4 inhibitors on protein expression of
NSCLC cell lines with inactivated p53 and PTEN. Quantification of (a)
pFAK, (b) pAKTand (c) pERK level in NCI-H460p53-/PTEN- cells and (d)
pFAK, (e) pAKT and (f) pERK in COR-L23 cells after treatments with
PF-573228 and WZ811. The data are expressed as the level of phospho-
protein relative to total protein level, all normalized to β-actin or
GAPDH, from at least three independent experiments and they are
presented as mean value ± S.E. * indicates p < 0.05 compared to
untreated cells. Each graph is accompanied by representative Western
blot
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inoculation, while in NCI-H460 xenografts, the first tumor
was observed at day 17 post cells’ inoculation. Even greater
difference was observed when 100,000 cells were inoculated.
COR-L23 xenografts developed the first palpable tumor at
day 9, while in NCI-H460 xenografts the first palpable tumor
observed at day 14 after inoculation (Table 1). Further to that,
xenografts developed in SCID mice after inoculation of 106
cells of NCI-H460 or COR-L23 cell lines were used to eval-
uate tumor growth rate. Similar to the previous experiment,
COR-L23 derived xenografts first formed palpable tumor, but
after the 25th day NCI-H460 cells started to grow faster than
COR-L23 cells and at the end of the experiment tumor derived
from NCI-H460 was 1.5 volume of COR-L23 derived tumor
(Fig. 7a). However, t-test analysis did not show any statisti-
cally significant difference in NCI-H460 and COR-L23 de-
rived tumor volume.
Further, we investigated the in vivo capacity of NCI-H460
and COR-L23 cells to invade lung parenchyma. NCI-H460
and COR-L23 cells were implanted in the pleural cavity of
SCID mice to obtain an orthotopic metastatic tumor model.
1 × 106 and 5 × 105 tumor cells were inoculated into the
pleural space and survival time was followed. Specifically,
at 1 × 106 inoculation density there was no difference in sur-
vival between NCI-H460 and COR-L23 bearing animals (data
not shown). However, at 5 × 105 inoculation density, we ob-
served a trend of shorter survival time (Fig. 7b; p = 0.076) in
animals bearing the COR-L23 tumor, with a median survival
time of 24 days for COR-L23 tumors and 28 days for NCI-
H460 tumors. Moreover, at day 14, the metastatic tumor pro-
gression in the pleural cavity was very aggressive for both cell
lines, but in animals bearing the COR-L23 derived tumor
distant metastases were seen in peritoneal organs, such as
liver, colon and pancreas (Fig. 7c).
Finally, we evaluated the potential of CXCR4 and FAK
inhibitors to suppress a metastatic progression of COR-L23
derived tumor in orthotopic metastatic NSCLC model.
Although no statistical analysis could be performed here due
to the small group size, the results suggest that both PF-
573228 and WZ811 demonstrated a trend of the life span
increase in the tumor-bearing treated mice (Fig 7d).
Particularly,WZ811was found to prolong the median survival
by 4 days (20% increase, median survival for treated mice
24 days as compared to a median survival of 20 days for the
vehicle treated mice that served as controls).
Discussion
NSCLC represents one of the most aggressive malignant
diseases characterized by frequent and extensive appear-
ance of metastases. A number of different genes drive the
metastatic spread of NSCLC, including p53 and PTEN
tumor suppressors that regulate important signaling path-
ways involved in the cell migration and invasion [17, 18].
These two tumor suppressors are among the most com-
monly inactivated genes in human cancers. Individually,
they have very important roles in sustaining cellular ho-
meostasis but they are also involved in complex regulatory
interactions [26]. However, their simultaneous inactivation
has different implications in pathogenesis of various cancer
types [27–30]. Specifically, co-inactivation of TP53 and
PTEN has been shown to be a significant characteristic of
NSCLC patients, particularly of those with a positive
lymph node invasion [16]. Nevertheless, their cooperative
role in promoting the metastatic phenotype of NSCLC has
not been studied so far.
To test the effects of simultaneous inactivation of p53 and
PTEN tumor suppressors on invasive characteristics of
NSCLC cells, we used the NCI-H460 large cell carcinoma
line that expresses wild type p53 and PTEN which we subse-
quently pharmacologically inhibited using the well-known in-
hibitors PFT-α and/or bpV(HOpic), respectively. Specificity
and efficacy of the applied inhibitors at used concentrations
have been reported in previous publications [25, 31].
Additionally, we employed another large cell lung carcinoma
cell line, COR-L23, as a model with intrinsically suppressed
function of both tumor suppressors. In accordance with previ-
ously published clinical data [16], COR-L23 and p53/PTEN
deficient NCI-H460 cells exhibited the most aggressive phe-
notype. These cells had significantly higher ability to migrate,
invade and degrade gelatin compared to the wild type cells, as
well as cells with individually inactivated single tumor sup-
pressors. Similarly, a recent study on glioblastoma cell lines
Table 1 In vivo
tumorigenicity assay Day NCI-H460 COR-L23
Inoculation density 10,000 cellsa
NoTb / NoIc NoT / NoI
15 0 / 6 1 / 6
17 1 / 6 3 / 6
22 5 / 6 6 / 6
25 6 / 6 6 / 6
Inoculation density 100,000 cellsa
NoT / NoI NoT / NoI
9 0 / 6 1 / 6
11 0 / 6 2 / 6
14 2 / 6 6 / 6
17 6 / 6 6 / 6
a In vivo tumorigenicity assay, mice were
injected subcutaneously with 10,000 or
100,000 NCI-H460 and COR-L23 cells
in each flank of NSGmice. Tumors forma-
tion was evaluated daily by palpation; b
Number of tumors formed; c Number of
inoculated tumors
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has shown that p53/PTEN deficient cells exhibited the highest
invasive potential through matrix and underlying porous
membrane [32]. Moreover, p53 and PTEN were shown to
have cooperative anti-invasive effects in Src-transformed vas-
cular smoothmuscle cells and fibroblasts by antagonizing Src/
Stat3 pathway and repressing Src-induced podosome forma-
tion [33, 34]. In addition, our results show more pronounced
invasive phenotype of COR-L23 cells compared to NCI-
H460p53-/PTEN- cells. This could be possibly attributed to the
limited efficiency of p53 and PTEN inhibition in NCI-H460
cells. Additionally, other inherent differences between the two
cell lines could affect invasive capacity of COR-L23 cells.
Individually, PTEN and p53 act as negative regulators of
CXCR4 and FAK expression. Namely, p53 represses tran-
scription of both FAK and CXCR4, while PTEN dephosphor-
ylates FAK and modulates CXCR4 expression through AKT
signaling [11–14]. However, the effects of simultaneous inhi-
bition of p53 and PTEN on CXCR4 and FAK expression and
activation of their signaling pathways are poorly studied.
Djuzenova and colleagues observed that glioblastoma cell
lines carrying mutations in p53 or PTEN exhibited a moder-
ately increased level of total FAK and phospho-FAK (Ser910)
while the phosphorylation of FAK (Tyr397) was abolished
[32]. Our results showed that FAK gene expression was in-
creased in COR-L23 cells while the level of pFAK (Tyr397)
was elevated in both COR-L23 and NCI-H460 cells with
functionally inhibited p53 and PTEN. CXCR4 mRNA and
protein levels were increased in both COR-L23 and NCI-
H460cells with co-inhibited p53 and PTEN. Finally, the activ-
ity of downstream signalingmolecules, pAKTand pERK,was
increased in both cell lines with inactive p53 and PTEN, im-
plying a key role of dual p53/PTEN inactivation for complete
activation of CXCR4 and FAK signaling pathways. Similarly
to the differences in invasive properties between the two cell
lines, the levels of all investigated proteins were higher in
COR-L23 cells. This could be also assigned to the incomplete
Fig. 7 In vivo tumorigenicity, metastatic spread and anti-invasive
treatment of COR-L23 derived tumors. a Growth rate of NCI-H460 and
COR-L23 derived tumors in SCID mice. b Survival curves of animals
bearing tumors derived upon inoculation of 5 × 105 of NCI-H460 and
COR-L23 cells in the pleural cavity of SCID mice. cMetastatic spread of
COR-L23 compared to NCI-H460 derived tumors in orthotopic
metastatic tumor model; arrows indicate tumor masses in pleural cavity
and distant organs. d Survival curves of COR-L23 tumor-bearing mice
treated with PF-573228 and WZ811, as well as vehicle control
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inhibition of p53 and PTEN in NCI-H460 cells, as well as
other inherent differences between the two cell lines.
Consequently, targeting CXCR4 and FAK in NSCLC cells
with co-inactivated p53 and PTEN was used to suppress their
invasive potential. Our results demonstrated that inhibition of
CXCR4 and FAK with respective inhibitors significantly sup-
pressed ability of NCI-H460p53-/PTEN- and COR-L23 cells to
migrate, invade and degrade gelatin. We observed that both
WZ811 and PF-573228 achieved their anti-invasive effects in
NCI-H460p53-/PTEN- cells, at least partially, by reducing the
activity of FAK and AKT. This is in accordance with the fact
that CXCR4-induced migration can be mediated by PI3 ki-
nase activation of FAK and/or AKT [8] while FAK can also
function upstream of PI3K/AKT [35]. However, in COR-L23
cells only FAK inhibitor decreased level of pFAK and pAKT.
The absence of any WZ811 effects on the studied proteins
may suggest the involvement of other signaling pathways that
need to be further elucidated. ERK pathway remained un-
changed in both cell lines upon all treatments. This is in line
with findings that CXCR4 signaling goes through the
PI3K/Akt pathway when PTEN is inactive [36] and that
FAK inhibition predominantly activates AKT rather than
ERK signaling in lung cancer [37].
Several in vivo studies, on sarcoma, breast, bladder and
prostate carcinomas, have shown that dual p53/PTEN sup-
pression causes highly aggressive phenotype with pronounced
metastatic behavior that leads to a significantly decreased sur-
vival [38–41]. Consequently, we extended the study to animal
models of lung carcinoma, using orthotopic metastatic model
of NSCLC in which we observed a tendency of decreased
survival among mice with inoculated COR-L23 cells. Since
NCI-H460 and COR-L23 cells did not show a statistically
significant difference in regard to their tumorigenic potential
in both NSG and SCID mice, shorter life span of COR-L23
tumor bearing animals could be attributed to COR-L23 tumor
invasiveness and development of distant metastasis. Several
targeted inhibitors, such as eEF2K and PARP/PI3K inhibitors,
were successfully used to suppress growth of p53/PTEN de-
ficient xenografts of different cancer types [41, 42]. However,
our study is the first one that targeted CXCR4 and FAK in
orthotopic models of p53/PTEN deficient tumors. We further
observed a trend of slightly prolonged survival of animals
with orthotopically inoculated COR-L23 cells upon treat-
ments with WZ811 and PF-573228. These data suggest that
CXCR4 and FAK can be useful as targets to suppress the
aggressiveness of p53/PTEN deficient tumors. However, the
lack of an appropriate statistical analysis in these experiments
implies a need for a much more detailed evaluation of other
CXCR4 and FAK inhibitors with better bioavailability, and
possibly alternative methods of administration.
Overall, our study demonstrated that p53/PTEN deficient
NSCLC cells have particularly invasive phenotype associated
with hyperactivation of CXCR4 and FAK signaling pathways.
Our results point out the importance of subclassifying NSCLC
patients according to p53 and PTEN functional status and to
the potential of using CXCR4 and FAK inhibition to suppress
metastatic spread of particularly aggressive p53/PTEN defi-
cient tumors.
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